Roivant Sciences Ltd (NAS:ROIV)
$ 12.71 0.02 (0.16%) Market Cap: 9.25 Bil Enterprise Value: 3.92 Bil PE Ratio: 2.25 PB Ratio: 1.81 GF Score: 61/100

Roivant Sciences Ltd at Credit Suisse Healthcare Conference Transcript

Nov 09, 2022 / 12:25AM GMT
Release Date Price: $5.07 (+1.40%)
Peter Crane

Hello, everyone. Good afternoon. My name is Peter Crane. I'm with the Banking team here at Credit Suisse. I'm here to introduce to you, Richard Pulik. Richard Pulik is the CFO of Roivant. He's been a colleague, good friend of mine since first year at Roivant. So thank you, Richard, for coming to speak to us, and please take it away.

Richard Pulik
Roivant Sciences Ltd. - CFO

Thank you so much, and thank you to the Credit Suisse team for the invitation. I just wanted to take you through a few updates. I think, obviously, as you've seen, we adjusted a -- so at first, I want to just point out the disclaimer and the -- around some of the forward-looking statements on Page 2. I just wanted to level that sort of Roivant and who we are? I think the mission and vision of the company is really to redefine a big pharma from end to end. As you can see, the company has had 6 FDA approvals from Vants launched by Roivant and it's 8 year history. I think that's pretty incredible for a fairly young company. We've had 8 consecutive positive Phase III trials, and we had our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot